口服阿扎胞苷联合罗米地辛治疗外周T细胞淋巴瘤的多中心2期研究
这项多中心2期研究评估口服阿扎胞苷联合罗米地辛在初治或复发难治外周T细胞淋巴瘤(PTCL)患者中的疗效。25例患者中总缓解率61%、完全缓解率48%,tTFH表型患者缓解率更高(80%和67%)。常见3-4级不良事件为血小板减少(48%)、中性粒细胞减少(40%)。
要点
- 联合方案在PTCL中总缓解率61%,完全缓解率48%。
- tTFH表型患者ORR 80%、CR率67%,生存尤其长。
- 常见3-4级不良事件为血小板减少48%、中性粒细胞减少40%。
核心结论
- 口服阿扎胞苷联合罗米地辛在PTCL患者中高度有效,可作为新方案的平台。
研究设计与样本
- 多中心2期研究,纳入25例初治或复发难治PTCL患者。
- 给药方案为阿扎胞苷300 mg每日一次第1-14天,罗米地辛14 mg/m2第8、15、22天,每35天重复。
- 主要终点为总缓解率(ORR),并对肿瘤样本进行靶向二代测序分析突变谱与缓解的相关性。
主要发现
- 25例患者中ORR为61%,完全缓解率为48%。
- tTFH表型患者ORR为80%,完全缓解率为67%。
- 中位随访13.5个月时,中位无进展生存期8.0个月,中位缓解持续时间20.3个月,中位总生存期未达到。
- 复发难治患者的中位无进展生存期和中位总生存期分别为8.0个月和20.6个月。
- 缓解者中参与DNA甲基化和组蛋白去乙酰化基因的平均突变数更高。
关键数值与推荐
- 最常见3-4级不良事件:血小板减少48%、中性粒细胞减少40%、淋巴细胞减少32%、贫血16%。
临床怎么用
- 联合方案可用于初治或复发难治PTCL患者,尤其tTFH表型可能获益更显著。
- 治疗期间需重点监测血小板减少和中性粒细胞减少等血液学毒性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Peripheral T-cell lymphomas (PTCLs) are uniquely vulnerable to epigenetic modifiers. We demonstrated in vitro synergism between histone deacetylase inhibitors and DNA methyltransferase inhibitors in preclinical models of T-cell lymphoma. In a phase 1 trial, we found oral 5-azacytidine and romidepsin to be safe and effective, with lineage-selective activity among patients with relapsed/refractory (R/R) PTCL. Patients who were treatment naïve or who had R/R PTCL received azacytidine 300 mg once per day on days 1 to 14, and romidepsin 14 mg/m2 on days 8, 15, and 22 every 35 days. The primary objective was overall response rate (ORR). Targeted next-generation sequencing was performed on tumor samples to correlate mutational profiles and response. Among 25 enrolled patients, the ORR and complete response rates were 61% and 48%, respectively. However, patients with T-follicular helper cell (tTFH) phenotype exhibited higher ORR (80%) and complete remission rate (67%). The most frequent grade 3 to 4 adverse events were thrombocytopenia (48%), neutropenia (40%), lymphopenia (32%), and anemia (16%). At a median follow-up of 13.5 months, the median progression-free survival, duration of response, and overall survival were 8.0 months, 20.3 months, and not reached, respectively. The median progression-free survival and overall survival were 8.0 months and 20.6 months, respectively, in patients with R/R disease. Patients with tTFH enjoyed a particularly long median survival (median not reached). Responders harbored a higher average number of mutations in genes involved in DNA methylation and histone deacetylation. Combined azacytidine and romidepsin are highly active in PTCL patients and could serve as a platform for novel regimens in this disease. This trial was registered at www.clinicaltrials.gov as #NCT01998035.
引用
- Falchi L, Ma H, Klein S, et al. Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study. Blood. 2021. PMID: 33171487. doi:10.1182/blood.2020009004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。